MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

Immunocompromised individuals are at increased risk of Staphylococcus aureus pneumonia. Neutralization of alpha-toxin (AT) with the monoclonal antibody (MAb) MEDI4893* protects normal mice from S. aureus pneumonia; however, the effects of the MAb in immunocompromised mice have not been reported. In...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Hua, L., Cohen, T. S., Shi, Y., Datta, V., Hilliard, J. J., Tkaczyk, C., Suzich, J., Stover, C. K., Sellman, B. R.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505239/
https://ncbi.nlm.nih.gov/pubmed/25987629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00510-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars